Depression Clinical Trial
— CBTOfficial title:
Testing Different Modes of Cognitive Behavior Therapy
Verified date | February 2024 |
Source | Northwestern University |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The purpose of this study is to test a novel behavioral treatment - Adapted Cognitive-Behavior Therapy (ACBT) - against standard Cognitive Behavior Therapy (CBT). The goal of the study is to determine if ACBT confers improved outcomes for women with depression and low literacy. Depression is a serious women's health issue. According to the World Health Organization, depression is the leading cause of disability worldwide with females reporting symptoms of depression at almost twice the rate of males. This study will provide pilot data to enable us to determine the effect size needed to detect a between-groups change in depression scores. The overall impact of this study will be empirical support for a novel form of treatment for women with depression, who also may lack adequate literacy, educational, or cognitive ability required to benefit from standard CBT.
Status | Completed |
Enrollment | 22 |
Est. completion date | November 15, 2023 |
Est. primary completion date | November 15, 2023 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | Female |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: 1. 18 years of age or older 2. female 3. diagnosis of major depressive disorder (MDD) according to DSM-5 (Diagnostic and Statistical Manual-5) (and no specifiers that pertain to exclusionary criteria (e.g. MDD with psychotic features) 4. able and willing to give informed consent 5. able to communicate in English 6. willingness to be randomized to therapy 7. willing to complete all study assessments 8. at baseline, no plans to move from the Chicago area during the duration of the study Exclusion Criteria: 1. history of bipolar disorder 2. history of psychosis 3. current substance use disorder of moderate or severe level of severity 4. suicidal intentions or actions within the past three months 5. known neurologic disease (e.g., multiple sclerosis, Parkinson's disease, cerebrovascular accident) and/or cognitive or neurologic impairment (e.g., Alzheimer's disease) 6. current participation in other psychotherapy (not including psychiatric appointments pertaining to medication management) 7. inadequate vision or hearing to interact with study materials 8. being a prisoner, detainee, or being in police custody 9. any current involvement in litigation |
Country | Name | City | State |
---|---|---|---|
United States | James W. Griffith | Chicago | Illinois |
Lead Sponsor | Collaborator |
---|---|
Northwestern University |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Patient Global Impression of Change (PGIC): Post-treatment (defined as completing 12 sessions of therapy; this will occur an estimated 12-14 weeks after initial intake interview) | Allows for the participant to indicate change in either direction (ie, much better, much worse) | Post-treatment which is within 2 weeks after final therapy session (i.e. estimated 12-14 weeks after initial intake interview) | |
Other | Patient Global Impression of Change (PGIC) 3-month follow-up (defined as 3 months after the end of treatment) | Allows for the participant to indicate change in either direction (ie, much better, much worse) | 3-month follow up (i.e., 3 months after the end of treatment) | |
Other | California Psychotherapy Alliance Scale - Participant version short-form - Post-treatment (defined as completing 12 sessions of therapy; this will occur an estimated 12-14 weeks after initial intake interview) | Measures four independent dimensions of the therapeutic relationship | Post-treatment which is within 2 weeks after final therapy session (i.e. estimated 12-14 weeks after initial intake interview) | |
Primary | PROMIS Depression: Post-treatment (defined as completing 12 therapy session) | Defined remission of MDD (partial or full) established by PROMIS (Patient-Reported Outcomes Measurement Information System). | Post-treatment which is within 2 weeks after final therapy session (i.e. estimated 12-14 weeks after initial intake interview) | |
Primary | PROMIS Depression: : 3-month follow-up (defined as 3 months after the last (i.e., 12th) session of cognitive behavior therapy. | Defined remission of MDD (partial or full) established by PROMIS. | 3-month follow up (i.e., 3 months after the end of treatment) | |
Secondary | World Health Organization Disability Assessment Schedule 2.0 (WHODAS 2.0): Post-treatment (defined as completing 12 sessions of therapy; this will occur an estimated 12-14 weeks after initial intake interview) | The 12-item WHODAS 2.0 is a measure of functional impairment. Higher scores indicate a higher level of impairment.
The scores for each item range from 0-4; the WHO scoring algorithm converts the summed score to a 0-100% score. The post-treatment score will be compared to baseline to quantify reduction of impairment after treatment. |
Post-treatment which is within 2 weeks after final therapy session (i.e. estimated 12-14 weeks after initial intake interview) | |
Secondary | World Health Organization Disability Assessment Schedule 2.0 (WHODAS 2.0): 3-month follow-up (defined as 3 months after the end of treatment) | The 12-item WHODAS 2.0 is a measure of functional impairment. Higher scores indicate a higher level of impairment.
The scores for each item range from 0-4; the WHO scoring algorithm converts the summed score to a 0-100% score. The 3-month follow-up score will be compared to baseline to quantify reduction of impairment after treatment. |
3-month follow up (i.e., 3 months after the end of treatment) |
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT05777044 -
The Effect of Hatha Yoga on Mental Health
|
N/A | |
Recruiting |
NCT04977232 -
Adjunctive Game Intervention for Anhedonia in MDD Patients
|
N/A | |
Recruiting |
NCT04680611 -
Severe Asthma, MepolizumaB and Affect: SAMBA Study
|
||
Recruiting |
NCT04043052 -
Mobile Technologies and Post-stroke Depression
|
N/A | |
Completed |
NCT04512768 -
Treating Comorbid Insomnia in Transdiagnostic Internet-Delivered Cognitive Behaviour Therapy
|
N/A | |
Recruiting |
NCT03207828 -
Testing Interventions for Patients With Fibromyalgia and Depression
|
N/A | |
Completed |
NCT04617015 -
Defining and Treating Depression-related Asthma
|
Early Phase 1 | |
Recruiting |
NCT06011681 -
The Rapid Diagnosis of MCI and Depression in Patients Ages 60 and Over
|
||
Completed |
NCT04476446 -
An Expanded Access Protocol for Esketamine Treatment in Participants With Treatment Resistant Depression (TRD) Who do Not Have Other Treatment Alternatives
|
Phase 3 | |
Recruiting |
NCT02783430 -
Evaluation of the Initial Prescription of Ketamine and Milnacipran in Depression in Patients With a Progressive Disease
|
Phase 2/Phase 3 | |
Recruiting |
NCT05563805 -
Exploring Virtual Reality Adventure Training Exergaming
|
N/A | |
Completed |
NCT04598165 -
Mobile WACh NEO: Mobile Solutions for Neonatal Health and Maternal Support
|
N/A | |
Completed |
NCT03457714 -
Guided Internet Delivered Cognitive-Behaviour Therapy for Persons With Spinal Cord Injury: A Feasibility Trial
|
||
Recruiting |
NCT05956912 -
Implementing Group Metacognitive Therapy in Cardiac Rehabilitation Services (PATHWAY-Beacons)
|
||
Completed |
NCT05588622 -
Meru Health Program for Cancer Patients With Depression and Anxiety
|
N/A | |
Recruiting |
NCT05234476 -
Behavioral Activation Plus Savoring for University Students
|
N/A | |
Active, not recruiting |
NCT05006976 -
A Naturalistic Trial of Nudging Clinicians in the Norwegian Sickness Absence Clinic. The NSAC Nudge Study
|
N/A | |
Enrolling by invitation |
NCT03276585 -
Night in Japan Home Sleep Monitoring Study
|
||
Completed |
NCT03167372 -
Pilot Comparison of N-of-1 Trials of Light Therapy
|
N/A | |
Terminated |
NCT03275571 -
HIV, Computerized Depression Therapy & Cognition
|
N/A |